Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Our ceo problem

<< Previous

Bullboard Posts

Next >>

Comment by biorunon May 30, 2024 12:22am

112 Views

Post# 36063677

RE:RE:RE:RE:RE:Our ceo problem

Don't mean to insult your business intelligence here, but how much effort in salary dollars do you think went into all the internal due diligence to bring it to the point of signing.

- scientific evaluation
- market studies
- legal costs
- safety consultation
- management time
- internal consultation with their global manager network
- corporate overhead allocated to the project cost center
- accounting/finance team verifications

All of that time added up is well beyond $1M, that is for sure.

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement